<DOC>
	<DOCNO>NCT00097409</DOCNO>
	<brief_summary>The purpose study determine effective safe new investigational drug treat persistent recurrent ovarian cancer patient receive platinum/taxane base chemotherapy whose disease continue progress . The treatment involve 1-hour treatment give intravenously ( IV ) , repeat every 21 day . A patient may continue receive treatment long benefiting treatment . Blood sample take specific time 24 hour period measure amount drug body specific time drug give . Blood sample also take routine lab test complete blood count clinical chemistry . Physical exam perform treatment .</brief_summary>
	<brief_title>Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Inclusion criterion : Must screen CA125 great equal 40 U/ml . Must receive one prior platinum/taxanebased chemotherapy regimen . Blood test do check blood count adequate take part study . Exclusion criterion : Received 1 chemotherapy regimen past less adequate liver kidney function . Females pregnant nursing . Any unstable , preexist major medical condition history cancer . Have receive investigational drug , chemotherapy , radiation treatment surgery within 28 day prior enter study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>platinum/taxane-refractory chemotherapy</keyword>
	<keyword>Persistent</keyword>
	<keyword>Recurrent</keyword>
</DOC>